See more : Namyang Dairy Products Co., Ltd (003920.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Chemed Corporation (CHE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Chemed Corporation, a leading company in the Medical – Care Facilities industry within the Healthcare sector.
You may be interested
- AptarGroup, Inc. (ATR) Income Statement Analysis – Financial Results
- Scinex Corporation (2376.T) Income Statement Analysis – Financial Results
- AB Fagerhult (publ.) (FAG.ST) Income Statement Analysis – Financial Results
- SILVERspac Inc. (SLVR) Income Statement Analysis – Financial Results
- ION Acquisition Corp 3 Ltd. (IACC) Income Statement Analysis – Financial Results
Chemed Corporation (CHE)
About Chemed Corporation
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in two segments, VITAS and Roto-Rooter. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company was incorporated in 1970 and is headquartered in Cincinnati, Ohio.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.26B | 2.13B | 2.14B | 2.08B | 1.94B | 1.78B | 1.67B | 1.58B | 1.54B | 1.46B | 1.41B | 1.43B | 1.36B | 1.28B | 1.19B | 1.15B | 1.10B | 1.02B | 926.48M | 735.34M | 308.87M | 314.18M | 477.12M | 500.69M | 453.60M | 381.30M | 341.70M | 683.80M | 699.20M | 645.00M | 525.10M | 401.00M | 352.30M | 599.40M | 591.80M | 500.60M | 391.00M | 359.50M | 372.70M |
| Cost of Revenue | 1.47B | 1.37B | 1.37B | 1.38B | 1.32B | 1.23B | 1.15B | 1.12B | 1.09B | 1.03B | 1.01B | 1.03B | 970.48M | 906.02M | 834.57M | 810.55M | 767.07M | 730.12M | 651.84M | 507.08M | 182.81M | 186.29M | 295.48M | 295.54M | 269.80M | 230.50M | 206.00M | 436.50M | 457.40M | 422.60M | 344.90M | 259.60M | 227.00M | 315.20M | 309.00M | 244.20M | 162.30M | 147.40M | 152.90M |
| Gross Profit | 796.55M | 765.09M | 769.80M | 701.39M | 617.43M | 554.00M | 516.19M | 461.45M | 455.78M | 421.61M | 404.52M | 396.72M | 385.49M | 374.53M | 355.66M | 338.39M | 332.99M | 288.46M | 274.64M | 228.26M | 126.06M | 127.89M | 181.64M | 205.15M | 183.80M | 150.80M | 135.70M | 247.30M | 241.80M | 222.40M | 180.20M | 141.40M | 125.30M | 284.20M | 282.80M | 256.40M | 228.70M | 212.10M | 219.80M |
| Gross Profit Ratio | 35.18% | 35.84% | 35.98% | 33.73% | 31.85% | 31.08% | 30.97% | 29.26% | 29.53% | 28.95% | 28.62% | 27.74% | 28.43% | 29.25% | 29.88% | 29.45% | 30.27% | 28.32% | 29.64% | 31.04% | 40.81% | 40.71% | 38.07% | 40.97% | 40.52% | 39.55% | 39.71% | 36.17% | 34.58% | 34.48% | 34.32% | 35.26% | 35.57% | 47.41% | 47.79% | 51.22% | 58.49% | 59.00% | 58.98% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 322.92M | 358.73M | 366.73M | 330.22M | 305.71M | 270.21M | 276.65M | 243.57M | 237.82M | 220.12M | 212.52M | 208.66M | 202.26M | 201.96M | 197.43M | 175.33M | 184.06M | 161.18M | 151.67M | 138.29M | 105.90M | 95.51M | 146.71M | 148.23M | 136.90M | 113.40M | 100.90M | 197.20M | 190.60M | 177.60M | 143.90M | 117.00M | 107.70M | 226.40M | 211.60M | 194.20M | 169.50M | 159.10M | 162.50M |
| Selling & Marketing | 72.20M | 68.60M | 62.10M | 54.40M | 49.50M | 47.00M | 40.90M | 37.20M | 36.40M | 32.80M | 31.00M | 29.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 395.12M | 358.73M | 366.73M | 330.22M | 305.71M | 270.21M | 276.65M | 243.57M | 237.82M | 220.12M | 212.52M | 208.66M | 202.26M | 201.96M | 197.43M | 175.33M | 184.06M | 161.18M | 151.67M | 138.29M | 105.90M | 95.51M | 146.71M | 148.23M | 136.90M | 113.40M | 100.90M | 197.20M | 190.60M | 177.60M | 143.90M | 117.00M | 107.70M | 226.40M | 211.60M | 194.20M | 169.50M | 159.10M | 162.50M |
| Other Expenses | 60.87M | 62.86M | 60.04M | -18.51M | 54.34M | 287.00K | 8.43M | 2.06M | -270.00K | 3.19M | 4.94M | 3.66M | 29.50M | 29.04M | 31.89M | 27.51M | 26.18M | 22.30M | 43.58M | 31.87M | 12.05M | 13.59M | 16.11M | 23.45M | 20.10M | 17.30M | 15.20M | 18.80M | 18.20M | 15.80M | 13.10M | 9.20M | 8.10M | 23.10M | 21.70M | 19.30M | 16.50M | 14.60M | 13.90M |
| Operating Expenses | 455.99M | 421.59M | 426.77M | 311.71M | 360.05M | 310.37M | 403.16M | 282.70M | 271.32M | 253.19M | 244.91M | 240.30M | 231.76M | 231.01M | 229.32M | 205.54M | 210.24M | 183.49M | 195.25M | 170.16M | 117.95M | 109.10M | 162.82M | 171.68M | 157.00M | 130.70M | 116.10M | 216.00M | 208.80M | 193.40M | 157.00M | 126.20M | 115.80M | 249.50M | 233.30M | 213.50M | 186.00M | 173.70M | 176.40M |
| Cost & Expenses | 1.92B | 1.79B | 1.80B | 1.69B | 1.68B | 1.54B | 1.55B | 1.40B | 1.36B | 1.29B | 1.25B | 1.27B | 1.20B | 1.14B | 1.06B | 1.02B | 977.30M | 913.61M | 847.09M | 677.24M | 300.76M | 295.38M | 458.30M | 467.22M | 426.80M | 361.20M | 322.10M | 652.50M | 666.20M | 616.00M | 501.90M | 385.80M | 342.80M | 564.70M | 542.30M | 457.70M | 348.30M | 321.10M | 329.30M |
| Interest Income | 6.27M | 355.00K | 377.00K | 757.00K | 513.00K | 671.00K | 427.00K | 383.00K | 281.00K | 0.00 | 847.00K | 809.00K | 426.00K | 444.00K | 423.00K | 743.00K | 3.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.11M | 4.58M | 1.87M | 2.36M | 4.54M | 4.99M | 4.27M | 3.72M | 3.65M | 8.22M | 15.04M | 14.72M | 13.89M | 11.96M | 11.60M | 5.99M | 11.24M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 60.87M | 59.17M | 59.05M | 56.58M | 45.21M | 38.86M | 35.63M | 34.64M | 33.50M | 33.07M | 32.39M | 30.52M | 29.50M | 29.04M | 27.90M | 27.51M | 26.57M | 23.80M | 23.34M | 20.18M | 12.81M | 14.36M | 24.12M | 23.45M | 20.10M | 17.30M | 15.20M | 18.80M | 18.20M | 15.80M | 13.10M | 9.20M | 8.10M | 23.10M | 21.70M | 19.30M | 16.50M | 14.60M | 13.90M |
| EBITDA | 414.34M | 393.44M | 411.23M | 454.93M | 311.35M | 283.45M | 156.81M | 215.41M | 217.27M | 200.62M | 162.17M | 191.06M | 183.94M | 174.83M | 160.12M | 155.84M | 138.47M | 126.28M | 99.68M | 78.14M | 18.60M | 27.72M | 37.23M | 52.94M | 46.90M | 37.40M | 34.80M | 29.20M | 51.20M | 44.80M | 36.30M | 24.40M | 17.60M | 57.80M | 71.20M | 62.20M | 59.20M | 53.00M | 57.30M |
| EBITDA Ratio | 18.30% | 18.43% | 19.22% | 21.88% | 16.06% | 15.90% | 9.45% | 13.69% | 14.12% | 14.06% | 13.99% | 13.38% | 13.51% | 13.48% | 12.96% | 13.56% | 14.83% | 12.40% | 13.80% | 12.47% | 8.25% | 16.01% | 13.92% | 10.07% | 7.91% | 4.88% | 4.62% | 2.21% | 4.96% | 5.47% | 3.87% | 2.47% | 0.62% | 9.19% | 11.41% | 11.95% | 14.32% | 17.80% | 13.31% |
| Operating Income | 340.57M | 343.50M | 343.04M | 389.68M | 257.38M | 243.63M | 113.04M | 178.75M | 184.46M | 168.42M | 133.39M | 156.42M | 153.73M | 143.52M | 126.35M | 132.86M | 122.76M | 104.98M | 79.38M | 58.11M | -7.72M | -1.55M | 18.82M | 33.47M | 26.80M | 20.10M | 19.60M | 31.30M | 33.00M | 29.00M | 23.20M | 15.20M | 9.50M | 34.70M | 49.50M | 42.90M | 42.70M | 38.40M | 43.40M |
| Operating Income Ratio | 15.04% | 16.09% | 16.04% | 18.74% | 13.28% | 13.67% | 6.78% | 11.34% | 11.95% | 11.56% | 9.44% | 10.94% | 11.34% | 11.21% | 10.62% | 11.56% | 11.16% | 10.31% | 8.57% | 7.90% | -2.50% | -0.49% | 3.94% | 6.68% | 5.91% | 5.27% | 5.74% | 4.58% | 4.72% | 4.50% | 4.42% | 3.79% | 2.70% | 5.79% | 8.36% | 8.57% | 10.92% | 10.68% | 11.64% |
| Total Other Income/Expenses | 9.80M | -13.82M | 7.28M | 6.31M | 4.23M | -4.03M | 3.88M | -1.70M | -4.33M | -5.67M | -9.57M | -12.94M | -13.17M | -9.69M | -5.73M | -10.51M | -20.92M | -14.70M | -24.73M | -21.02M | 7.67M | -18.42M | -29.15M | -2.54M | 4.20M | 12.00M | 8.30M | 11.00M | 3.00M | -3.50M | 3.20M | 5.60M | 6.90M | -7.70M | -8.10M | -8.60M | -5.60M | -22.60M | -2.90M |
| Income Before Tax | 350.37M | 329.68M | 350.31M | 395.99M | 261.61M | 239.60M | 116.92M | 177.05M | 180.13M | 162.75M | 123.83M | 145.82M | 140.56M | 133.83M | 120.62M | 122.35M | 101.84M | 90.28M | 57.28M | 37.09M | 1.25M | -1.28M | -10.06M | 33.25M | 31.00M | 32.10M | 27.90M | 53.60M | 36.00M | 25.50M | 26.40M | 20.80M | 16.40M | 27.00M | 41.40M | 34.30M | 37.10M | 15.80M | 40.50M |
| Income Before Tax Ratio | 15.47% | 15.44% | 16.38% | 19.04% | 13.50% | 13.44% | 7.01% | 11.23% | 11.67% | 11.18% | 8.76% | 10.20% | 10.37% | 10.45% | 10.13% | 10.65% | 9.26% | 8.86% | 6.18% | 5.04% | 0.40% | -0.41% | -2.11% | 6.64% | 6.83% | 8.42% | 8.17% | 7.84% | 5.15% | 3.95% | 5.03% | 5.19% | 4.66% | 4.50% | 7.00% | 6.85% | 9.49% | 4.39% | 10.87% |
| Income Tax Expense | 77.86M | 80.06M | 81.76M | 76.52M | 41.69M | 34.06M | 18.74M | 68.31M | 69.85M | 63.44M | 46.60M | 56.52M | 54.58M | 52.00M | 46.58M | 50.24M | 39.06M | 32.56M | 19.58M | 13.80M | 4.75M | 6.85M | -3.36M | 12.66M | 11.30M | 12.20M | 10.80M | 21.90M | 15.60M | 11.00M | 9.30M | 6.50M | 5.40M | 10.40M | 15.20M | 13.70M | 16.70M | 9.00M | 18.60M |
| Net Income | 272.51M | 249.62M | 268.55M | 319.47M | 219.92M | 205.54M | 98.18M | 108.74M | 110.27M | 99.32M | 77.23M | 89.30M | 85.98M | 81.83M | 73.78M | 71.02M | 63.98M | 50.65M | 35.82M | 27.51M | -3.44M | -1.81M | -10.38M | 20.58M | 19.70M | 19.90M | 30.30M | 32.30M | 23.10M | 43.90M | 19.50M | 15.70M | 52.90M | 16.60M | 26.20M | 21.90M | 20.40M | 36.80M | 21.90M |
| Net Income Ratio | 12.03% | 11.69% | 12.55% | 15.36% | 11.34% | 11.53% | 5.89% | 6.90% | 7.14% | 6.82% | 5.46% | 6.24% | 6.34% | 6.39% | 6.20% | 6.18% | 5.82% | 4.97% | 3.87% | 3.74% | -1.11% | -0.58% | -2.17% | 4.11% | 4.34% | 5.22% | 8.87% | 4.72% | 3.30% | 6.81% | 3.71% | 3.92% | 15.02% | 2.77% | 4.43% | 4.37% | 5.22% | 10.24% | 5.88% |
| EPS | 18.11 | 16.72 | 17.14 | 20.02 | 13.77 | 12.80 | 6.11 | 6.64 | 6.54 | 5.79 | 4.24 | 4.72 | 4.19 | 3.62 | 3.29 | 3.08 | 2.61 | 1.94 | 1.40 | 1.14 | -0.17 | -0.09 | -0.53 | 1.01 | 0.93 | 0.99 | 1.52 | 1.65 | 1.18 | 2.23 | 1.00 | 0.80 | 2.64 | 0.80 | 1.31 | 1.19 | 1.14 | 2.06 | 1.25 |
| EPS Diluted | 17.93 | 16.53 | 16.85 | 19.48 | 13.31 | 12.23 | 5.86 | 6.48 | 6.33 | 5.57 | 4.16 | 4.62 | 4.10 | 3.55 | 3.24 | 3.04 | 2.55 | 1.90 | 1.36 | 1.12 | -0.17 | -0.09 | -0.53 | 1.00 | 0.93 | 0.99 | 1.51 | 1.63 | 1.18 | 2.23 | 1.00 | 0.80 | 2.64 | 0.80 | 1.27 | 1.14 | 1.08 | 1.80 | 1.14 |
| Weighted Avg Shares Out | 15.05M | 14.93M | 15.67M | 15.96M | 15.97M | 16.06M | 16.06M | 16.38M | 16.87M | 17.17M | 18.20M | 18.92M | 20.52M | 22.59M | 22.45M | 23.06M | 24.52M | 26.12M | 25.55M | 24.12M | 19.85M | 19.72M | 19.43M | 19.67M | 20.94M | 20.12M | 19.88M | 19.58M | 19.72M | 19.71M | 19.60M | 19.63M | 20.08M | 20.75M | 20.08M | 18.48M | 17.89M | 17.86M | 17.59M |
| Weighted Avg Shares Out (Dil) | 15.20M | 15.10M | 15.94M | 16.40M | 16.53M | 16.80M | 16.74M | 16.79M | 17.42M | 17.84M | 18.59M | 19.34M | 20.95M | 23.03M | 22.74M | 23.37M | 25.08M | 26.67M | 26.30M | 24.64M | 19.91M | 19.77M | 19.43M | 19.85M | 21.03M | 20.20M | 20.03M | 19.82M | 19.72M | 19.71M | 19.60M | 19.63M | 20.08M | 20.75M | 20.63M | 19.30M | 18.98M | 20.44M | 19.30M |
Chemed (CHE) Q2 Earnings Miss Estimates, '23 EPS View Down
Chemed's (CHE) second-quarter 2023 performance reflects strength in the VITAS segment, while expenses weigh on margins.
Chemed (CHE) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Chemed (CHE) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Chemed (CHE) Q2 Earnings and Revenues Lag Estimates
Chemed (CHE) came out with quarterly earnings of $4.71 per share, missing the Zacks Consensus Estimate of $5.09 per share. This compares to earnings of $4.84 per share a year ago.
Chemed Reports Second-Quarter 2023 Results
CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation's largest providers of end-of-life care, and Roto-Rooter, the nation's largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its...
DVA vs. CHE: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Outpatient and Home Healthcare stocks have likely encountered both DaVita HealthCare (DVA) and Chemed (CHE). But which of these two companies is the best option for those looking for undervalued stocks?
Chemed To Report Second-Quarter 2023 Earnings July 26, Related Conference Call To Be Held On July 27
CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the second quarter ended June 30, 2023, on Wednesday, July 26, 2023, following the close of trading on the New York Stock Exchange. Chemed will host...
Here's Why You Should Retain Chemed (CHE) Stock for Now
Investors continue to be optimistic about Chemed (CHE) on the strength of the VITAS Healthcare and Roto-Rooter segments.
4 Stocks to Hold in a Challenging Outpatient Home Health Industry
Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, CHE, AMED and ADUS are well poised to gain.
Cincinnati Earnings Roundup: Part 1
The latest earnings season has come and gone.
Chemed Corporation to Present at the Jefferies 2023 Healthcare Conference
CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE: CHE) today announced that it will deliver a presentation at the Jefferies 2023 Healthcare Conference on Thursday, June 8, 2023, at approximately 11:30 a.m. (ET) at the New York Marriott Marquis in New York City. The...
Source: https://incomestatements.info
Category: Stock Reports